Eli Lilly and Stock Forecast, Price & News

Eli Lilly and's stock was trading at $140.02 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, LLY stock has increased by 51.7% and is now trading at $212.35.
View which stocks have been most impacted by COVID-19.

15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Eli Lilly and in the last year. There are currently 4 hold ratings, 10 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Eli Lilly and stock.
View analyst ratings for Eli Lilly and or view MarketBeat's top 5 stock picks.

Wall Street analysts have given Eli Lilly and a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Eli Lilly and wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

399 employees have rated Eli Lilly and CEO David A. Ricks on Glassdoor.com. David A. Ricks has an approval rating of 86% among Eli Lilly and's employees.

Eli Lilly and is scheduled to release its next quarterly earnings announcement on Friday, January 29th 2021.
View our earnings forecast for Eli Lilly and.

Eli Lilly and will be holding an earnings conference call on Friday, January 29th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Eli Lilly and Company (NYSE:LLY) announced its earnings results on Sunday, November, 1st. The company reported $1.54 earnings per share for the quarter, missing analysts' consensus estimates of $1.71 by $0.17. The company had revenue of $5.74 billion for the quarter, compared to the consensus estimate of $5.87 billion. Eli Lilly and had a trailing twelve-month return on equity of 166.45% and a net margin of 24.01%. The firm's quarterly revenue was up 4.8% on a year-over-year basis. During the same period in the prior year, the firm earned $1.48 EPS.
View Eli Lilly and's earnings history.

Eli Lilly and announced a quarterly dividend on Monday, December 14th. Investors of record on Friday, February 12th will be given a dividend of $0.85 per share on Wednesday, March 10th. This represents a $3.40 dividend on an annualized basis and a dividend yield of 1.60%. The ex-dividend date of this dividend is Thursday, February 11th. This is a boost from Eli Lilly and's previous quarterly dividend of $0.74.
View Eli Lilly and's dividend history.

Eli Lilly and pays an annual dividend of $2.96 per share and currently has a dividend yield of 1.44%. Eli Lilly and does not yet have a strock track record of dividend growth. The dividend payout ratio of Eli Lilly and is 49.01%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Eli Lilly and will have a dividend payout ratio of 37.09% next year. This indicates that Eli Lilly and will be able to sustain or increase its dividend.
View Eli Lilly and's dividend history.

Eli Lilly and updated its FY21 earnings guidance on Tuesday, December, 15th. The company provided EPS guidance of $7.75-8.40 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $8.00. The company issued revenue guidance of $26.5-28.0 billion, compared to the consensus revenue estimate of $26.39 billion.

15 Wall Street analysts have issued 1 year target prices for Eli Lilly and's stock. Their forecasts range from $144.00 to $225.00. On average, they expect Eli Lilly and's stock price to reach $179.57 in the next year. This suggests that the stock has a possible downside of 15.4%.
View analysts' price targets for Eli Lilly and or view Wall Street analyst' top-rated stocks.

Eli Lilly and saw a increase in short interest in December. As of December 31st, there was short interest totaling 6,890,000 shares, an increase of 24.1% from the December 15th total of 5,550,000 shares. Based on an average daily volume of 4,150,000 shares, the short-interest ratio is currently 1.7 days. Currently, 0.9% of the company's shares are short sold.
View Eli Lilly and's Short Interest.

Some companies that are related to Eli Lilly and include Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics Public (HZNP), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Corcept Therapeutics (CORT), Nektar Therapeutics (NKTR), Pacira BioSciences (PCRX), Endo International (ENDP) and Supernus Pharmaceuticals (SUPN).
View all of LLY's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Eli Lilly and investors own include Johnson & Johnson (JNJ), Pfizer (PFE), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Bristol-Myers Squibb (BMY), The Walt Disney (DIS), AT&T (T), Verizon Communications (VZ) and JPMorgan Chase & Co. (JPM).

Eli Lilly and trades on the New York Stock Exchange (NYSE) under the ticker symbol "LLY."

Eli Lilly and's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include New York State Teachers Retirement System (0.11%), OLD National Bancorp IN (0.07%), Strs Ohio (0.07%), Nisa Investment Advisors LLC (0.05%), Atalanta Sosnoff Capital LLC (0.04%) and Private Capital Advisors Inc. (0.04%). Company insiders that own Eli Lilly and stock include Aarti S Shah, Alfonso G Zulueta, Anne E White, Christi Shaw, David A Ricks, Donald A Zakrowski, Enrique A Conterno, Jackson P Tai, Joshua L Smiley, Lilly Endowment Inc, Melissa S Barnes, Michael J Harrington, Myles O'neill and Stephen F Fry.
View institutional ownership trends for Eli Lilly and.

LLY stock was sold by a variety of institutional investors in the last quarter, including Nisa Investment Advisors LLC, Hexavest Inc., New York State Teachers Retirement System, Gateway Investment Advisers LLC, Candriam Luxembourg S.C.A., Avantax Advisory Services Inc., Atalanta Sosnoff Capital LLC, and Vantage Investment Partners LLC. Company insiders that have sold Eli Lilly and company stock in the last year include Aarti S Shah, Alfonso G Zulueta, Lilly Endowment Inc, Melissa S Barnes, Myles O'neill, and Stephen F Fry.
View insider buying and selling activity for Eli Lilly and or view top insider-selling stocks.

LLY stock was bought by a variety of institutional investors in the last quarter, including Strs Ohio, Cadinha & Co. LLC, Crossmark Global Holdings Inc., Private Capital Advisors Inc., Sarasin & Partners LLP, Kestra Advisory Services LLC, Journey Advisory Group LLC, and Crescent Capital Consulting LLC. Company insiders that have bought Eli Lilly and stock in the last two years include Anne E White, David A Ricks, Jackson P Tai, and Joshua L Smiley.
View insider buying and selling activity for Eli Lilly and or or view top insider-buying stocks.

Shares of LLY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of LLY stock can currently be purchased for approximately $212.35.

Eli Lilly and has a market capitalization of $203.13 billion and generates $22.32 billion in revenue each year. The company earns $8.32 billion in net income (profit) each year or $6.04 on an earnings per share basis. Eli Lilly and employs 35,065 workers across the globe.

The official website for Eli Lilly and is www.lilly.com.

Eli Lilly and's mailing address is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. The company can be reached via phone at 317-276-2000 or via email at [email protected]